Healthcare

AbCellera is a Vancouver-based clinical-stage biotechnology company founded in 2012 that uses an AI- and microfluidics-driven antibody discovery platform to find and develop antibody-based medicines in endocrinology, women's health, immunology and oncology. It is shifting from partnership-based discovery toward an internal pipeline led by …

Bioventus is a Durham, North Carolina-based global medical device company that develops and commercializes minimally invasive active healing treatments for musculoskeletal conditions. It operates through Pain Treatments, including Durolane, Gelsyn-3 and Supartz FX plus peripheral nerve stimulation, Surgical Solutions, which includes bone graft substitutes …

Candel Therapeutics is a pre-revenue, clinical-stage biopharmaceutical company based in Needham, Massachusetts, developing off-the-shelf viral immunotherapies. They are designed to turn immunologically cold tumors into immune-responsive sites and trigger a systemic anti-tumor response. Its lead candidate, aglatimagene besadenovec, has generated Phase 3 data in …

City Therapeutics is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing next-generation RNA interference therapeutics. It priced an upsized IPO of about $200 million and has 75 employees. Its City Platform combines engineered trigger molecules, including proprietary cityRNA, tissue-selective targeting ligands and genetics-driven target selection …

DBV Technologies is a clinical-stage biopharmaceutical company based in Châtillon, France, with North American operations in Warren, New Jersey. Founded in 2002, it develops non-invasive epicutaneous immunotherapy for food allergies using its proprietary Viaskin patch platform. Its ordinary shares trade on Euronext Paris, and …

Fresenius Medical Care is a Bad Homburg, Germany-based provider of kidney care services and dialysis products, with a Frankfurt listing alongside its New York shares. Its Care Delivery segment, about 80% of revenue, operates roughly 3,500 to 3,600 outpatient dialysis clinics treating around 290,000 …

Humacyte is a Durham, North Carolina-based commercial-stage biotechnology platform company founded in 2004 and led by founder-scientist Laura Niklason. It develops universally implantable, bioengineered human acellular vessels designed to avoid immune rejection, and its FDA-approved product, Symvess, treats extremity vascular trauma. The pipeline targets …